Kaleido Biosciences is a clinical-stage biotechnology company that is developing the first therapeutic product aimed at systematically shaping the microbiome residing in the human body. The human microbiome, the genetic material of all the microbes that live on and inside the body, is one of the most important frontiers in modern medicine. It plays a central role in numerous severe metabolic, inflammatory and infectious diseases. Founded in January 2015 by Flagship VentureLabs, Kaleido has discovered a broad new means of driving the central functions of the human microbiome with applications spanning a wide range of important diseases. Led by Dr. Noubar Afeyan, who is also the founder, senior managing partner and CEO of Flagship Ventures, Boston-based Kaleido has accumulated more than 2,000 days of clinical data and has filed for intellectual property for over 90 different biomedical applications.